Charles River Laboratories (CRL)

Rating: HOLD

HOLD (5-tier) · mature cash generator · conviction: low

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -9% vs spot
• Monte Carlo median implies -18% vs spot
• DCF fair value implies -37% vs spot
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -60% vs spot
• Net: reward/risk of 0.3× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At 226.79 the shares trade near 20.4 times forward earnings and roughly 3.4 times EV/revenue, a multiple that discounts an orderly mid-cycle recovery: biopharma R&D spend re-accelerating, DSA demand normalising and operating margin drifting back toward 15%. Our probability-weighted target of 211.28 sits about 7% below spot. The disagreement is not about the multiple but about the earnings base and the odds of reaching it. The independent DCF anchors fair value at 143 to 153, well beneath the multiple-derived view, and the Monte Carlo puts only a 34.5% chance of finishing above today's price. The base case, roughly 11.14 in EPS at 19 times, recovers to 212 — not to spot. We rate the name HOLD: the distribution is skewed left, with the structural and recession scenarios carrying 37% of the weight, and peer-multiple support (peer median 22.6 times forward) is offset by thinner margins and a net-debt balance sheet. The clearest way to be wrong is a durable biopharma-funding contraction that converts this cyclical soft patch into a structural reset, driving earnings and the multiple toward the 92.53 structural target beneath the 144.26 low.

The dashboard below is the whole argument on one page: spot ($229) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear case treats the current weakness as a reset, not a dip. Biotech venture funding and large-pharma R&D budgets have contracted together, and CRO demand lags those decisions by several quarters. If DSA net book-to-bill stays below 1.0x, the Discovery and Safety Assessment franchise loses pricing power just as non-human-primate supply normalises and China capacity overhangs the market. Bioprocessing destocking compounds the revenue pressure. In that world operating margin compresses toward 10 to 11%, the growth premium the market once paid for a CRO compounder evaporates, and the multiple de-rates alongside the earnings. The 92.53 structural target — beneath the 52-week low of 144.26 — is the logical endpoint of that mechanism, not a tail.

Key Debate

P/E Multiple explains 49% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.51 vs analyst floor +0.01 → delta +0.51 (n=26 mgmt / 20 Q&A; 73th pctile across the S&P book, z +0.7).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 911 articles): avg ticker sentiment +0.16 (bullish 25% / bearish 6%)

Scenario Analysis

The tree runs from a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($92) to a 'Bull — Re-Rate' bull case ($376); the probability-weighted blend (PWEV $209) is -9% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $92). Structural impairment — biopharma-funding / China / bioprocessing reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 92.96; probability: 0.2.
• R&D-Spend Recession (17%, $159). Cyclical downturn — biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding weakens for 1–2 years before normalising. Drivers — implied_target: 157.87; probability: 0.17.
• Base — Tools + Services Growth (35%, $212). Mid-cycle — normalised biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding; disciplined capital allocation; steady returns. Drivers — implied_target: 219.26; probability: 0.35.
• Growth — Bioprocessing / Biologics Recovery (20%, $297). Upside — bioprocessing + biologics recovery lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 296.0; probability: 0.2.
• Bull — Re-Rate (8%, $376). Upside tail — sustained tight conditions or a structural re-rate on bioprocessing + biologics recovery. Drivers — implied_target: 373.84; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $187 + scenario PWEV $209, ≈ spot); the weighted blend $183 (-20%) sits below it because the cash-flow DCF ($143) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $187 and 34% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (49% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 16x terminal FCF multiple → $143. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 22.625x) implies $252. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 133% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Devices Tools

This name sits in the Health Devices Tools as a life_science_tools. biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)

Mapping note: name-level 'Structural — Biopharma-Funding / China / Bioprocessing Reset' (20%) + 'R&D-Spend Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — Bioprocessing / Biologics Recovery' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $2B + PV(terminal) $7B = EV $10B; + net cash → equity $7B ÷ diluted shares 0.05B = $143/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $153/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 13% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $252; EV/Rev → $421.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Life-Science Tools & Services multiple (AI re-rating) (base 19x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1.8% of revenue; cash conversion (OCF/NI) -520% — cash-backed.

Catalyst Calendar

• 2026-08-05 (~28d) — Quarterly earnings — est. EPS $2.72 (AV EARNINGS_CALENDAR)
• 2026-09-15 (~69d) — US FDA non-animal-testing / New Approach Methodologies (NAM) policy progression (authored)
• 2026-10-31 (~115d) — FY2027 organic-growth and DSA-recovery guidance framework (authored)
• 2027-01-31 (~207d) — Biopharma R&D-budget setting season read-through (large-pharma capex plans) (authored)

Forecast Track Record

• EPS surprise: beat 87.5% of the last 8 quarters; average surprise -7.6%.

Competitive Moat

Narrow moat. CRL's edge is regulatory embeddedness (validated safety-assessment sites, NHP supply, IND-enabling data trusted by FDA) rather than a wide franchise; it is real but demand-cyclical and China/NHP-exposed. FALSIFIABLE: if DSA net book-to-bill stays below 1.0x for a year, pricing power is failing and the terminal multiple should sit near the ~16x market, not the life-science-tools ~19-23x.

Moat sources:

• GLP-validated Safety Assessment sites with regulatory track record (switching cost + FDA familiarity)
• Non-human-primate (NHP) supply chain control and early-discovery model portfolio
• Integrated discovery-to-safety CRO breadth (fewer credible full-service competitors)
• ABSENCE of durable pricing power in RMS/China where NHP oversupply and local competition compress price

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 18.6× forward EPS, vs the house DCF terminal 16.0×, and a peer median 22.625×. The house DCF sits 37% below spot, so the market is pricing in more than the house case — roughly 3.0pp of revenue CAGR.

Variant perception: the house view is in-line with consensus, and the thesis is primarily growth-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 22.6× (simple median 22.625×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $144–$229, centre $182 (-20% vs spot); spot sits at the 100th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $376.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (76.0); Revenue CAGR ±3pp (54.0); Terminal × ±15% (45.0); Capex intensity ±15% (23.0); WACC ±1pp (17.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 16×, FY+5 revenue $5B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth (YoY, total company) below 2.0% organic (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Midpoint of the Base case (6% organic) and the R&D-Spend Recession case (-2% organic). Two prints below this line marks the cyclical soft patch turning into a demand reset rather than a pause.
• Non-GAAP operating margin below 14.1% (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Midpoint of Base op margin (15.2%) and R&D-Spend Recession op margin (13.0%). Sustained prints below this show negative operating leverage as fixed capacity carries lower volume.
• DSA (Discovery & Safety Assessment) net book-to-bill below 1.0x (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Book-to-bill under 1.0x for two quarters means the order backlog is shrinking and forward DSA revenue and pricing are set to erode — the leading indicator of the biopharma-funding channel weakening.
• Full-year organic revenue guidance revision cut any downward revision to the FY organic range (single event → Reimbursement / Funding / Utilization Reset). A cut to the guided FY organic range at any print signals management has lost confidence in the demand recovery embedded in the Base case, pulling the probability weight toward the recession and structural scenarios.
• China / NHP-linked revenue and pricing declining sequential decline with negative pricing commentary (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Persistent China softness and non-human-primate oversupply pressuring price is the specific channel through which the cyclical case becomes the Structural reset, where the multiple de-rates alongside earnings.

Fact / Inference / Speculation

• FACT: Spot $229; 52-week range $144–$229; engine rating HOLD; base-case target $211 (-8%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $183 (-20% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $183 (-20% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.